Article

Lung Cancer Drug Improves Survival in Patients with ALK-Positive Lymphoma

Xalkori improves survival in patients with ALK-positive lymphoma.

Developed to target the anaplastic lymphoma kinase (ALK) mutation, Xalkori (crizotinib) was approved for a subset of non-small cell lung cancers. The ALK mutation is also present in more than half of anaplastic large-cell lymphomas.

A study looking at the long-term effect of Xalkori in 11 participants with advanced ALK-positive lymphoma showed they experienced a near immediate regression of their disease, with nine participants having a complete response. Although the response was not long-lasting for some, four participants continue to have no signs of disease, and four have successfully gone on to other treatments, including transplantation or an investigational therapy. Subsequent analysis of blood taken from two participants whose disease progressed while on the experimental treatment uncovered new genetic mutations resistant to Xalkori that were not present before treatment.

Related Videos
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with a brown hair tied into a bun.